MiRNA-based Therapeutics for Lung Cancer

Curr Pharm Des. 2018 Feb 12;23(39):5989-5996. doi: 10.2174/1381612823666170714151715.

Abstract

Background: miRNA, a small non-coding RNA molecule containing about 22 nucleotides, functions in RNA silencing and post-transcriptional regulation of gene expression. With these qualities, miRNAs modulate multiple signaling pathways involved in cancer development, such as cellular proliferation, apoptosis, and migration.

Methods: The goal of this review is to discuss possible miRNAs-based therapeutic strategies, through defining performance of miRNAs in carcinogenesis, in particular in lung cancer.

Results: miRNA, a non-coding RNA, is divided into two main types: tumor suppressor miRNAs and oncogenic miRNAs. In addition, special processed miRNAs can be an assistant therapeutic tool.

Conclusion: In order to develope antitumor therapy, miRNAs-based therapeutic strategies are worth of deeper studies. In this process, the stability, effectiveness, and side effects should be considered.

Keywords: drug resistance; lung cancer; miRNA; oncogene; therapy; tumor suppressor.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / analysis*
  • Biomarkers, Tumor / genetics
  • Humans
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / drug therapy*
  • MicroRNAs / analysis*
  • MicroRNAs / genetics

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • MicroRNAs